Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH
inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who
have received standard therapy